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Background: Necrotizing enterocolitis is the leading cause of death from gastrointestinal diseases in premature newborns and is characterized by the loss of intestinal barrier functions. Erythropoietin which has the biological property to protect endothelial cell to cell barrier and has trophic action on villous height and bowel length is being used to reduce the incidence of feed intolerance and NEC.
Methods: we conducted a systematic review of randomized controlled trials (RCT) and non-RCTs to evaluate the efficacy of enteral administration of erythropoietin in reducing the incidence of NEC, using the Cochrane methodology and PRISMA statement (RCTs), MOOSE guidelines and RoBANS tool (non RCTs).
Results: We found 18 RCTs[IV EPO:10, Subcutaneous EPO:7, Enteral EPO:1, N = 3700],3 non-RCTs [Subcutaneous:2, Intramuscular :1, N = 680] and 7 experimental studies which showed the effet of rEPO on NEC. Meta-analysis of data (random effects model) from the 18 RCTs comparing rEPO versus placebo (N = 3700) indicated that rEPO administration (Median (IQR) dose:400 (300-750) U/Kg/day) significantly decreased the incidence of NEC [Risk ratio:0.74 (95% CI: 0.57, 0.96);p = 0.02]. (Fig  1) . Meta-analysis of data from the 3 non-RCTs (random effects model) showed no significant effect of rEPO on NEC [Odds ratio:0.63 (95% CI: 0.20,2.04); p = 0.44, Level of evidence:low]. Individually, the 7 experimental studies showed significant decrease in NEC following the administration of Epo irrespective of the route of administration: Enteral:3studies;p < 0.05, Subcutaneous:1 study; p < 0.05), Intraperitoneal: 1 study;p = 0.001 and Intracellular: 2 studies; p < 0.05. Meta-analysis could not be performed as the sample size was <10 and the outcome was assessed qualitatively in individual studies. Subgroup analysis showed that the effect Epo on NEC was observed only with the intravenous route (8 RCTs, N = 2320).
Conclusion: The current evidence suggests a possible benefit with prophylactic rEpo on NEC in preterm neonates. Large RCTs primarily designed to study the effects of EPO on NEC are urgently required. The effect of enteral Epo on NEC and long term neurodevelopmental outcomes also needs further research.
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